Taro Pharmaceutical Industries (NYSE:TARO) will issue its quarterly earnings data after the market closes on Wednesday, May 22nd. Analysts expect the company to announce earnings of $2.26 per share for the quarter.
Shares of TARO opened at $101.34 on Friday. The stock has a market capitalization of $4.02 billion, a PE ratio of 16.40 and a beta of 0.51. Taro Pharmaceutical Industries has a fifty-two week low of $76.93 and a fifty-two week high of $121.23.
TARO has been the topic of a number of research reports. Zacks Investment Research upgraded Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating and set a $114.00 target price on the stock in a report on Friday, February 8th. TheStreet upgraded Taro Pharmaceutical Industries from a “c” rating to a “b-” rating in a report on Friday, February 15th.
A hedge fund recently raised its stake in Taro Pharmaceutical Industries stock. Geode Capital Management LLC increased its position in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 124.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,255 shares of the company’s stock after purchasing an additional 4,018 shares during the quarter. Geode Capital Management LLC’s holdings in Taro Pharmaceutical Industries were worth $613,000 at the end of the most recent quarter. Institutional investors own 10.16% of the company’s stock.
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
See Also: Green Investing
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.